Research article Open access
Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia
Objectives: Chelating agents remain the mainstay in reducing the iron burden and extending patient survival in homozygous beta-thalassemia but adverse and toxic effects may increase with the institution and long term use of this essential therapy. This study aimed to estimate the incidence of deferasirox (DFX) side eff …